Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.5450 (6.41%) ($11.5450 - $11.6000) on Tue. Nov. 22, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.16% (three month average) | RSI | 75 | Latest Price | $11.5450(6.41%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 3.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(45%) IWM(44%) IWC(43%) IWN(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.58% in a week (0% probabilities). VIXM(-13%) VXX(-12%) XLU(-8%) TLT(-5%) VCIT(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.58% (StdDev 3.16%) | Hourly BBV | 2.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $11.05(4.48%) | 10 Day Moving Average | $11.14(3.64%) | 20 Day Moving Average | $10.76(7.3%) | To recent high | -9.7% | To recent low | 15.5% | Market Cap | $2.981b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |